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Abstract
Background: Anxiety disorders (ADs) are common with a high rate of medical comorbidities. Although the
association between ADs and the overall cancer risk remains controversial, patients with ADs were found to
be more likely to develop specific cancer types. Herein, we estimated the risk of developing urological cancers
among patients with ADs in a 5-year follow-up period using a population-based database.
Methods: Two study cohorts were identified from the Taiwan Longitudinal Health Insurance Database 2005:
patients with ADs, and comparison subjects selected by one-to-one matching for sex, age, and the year of
recruitment. Follow-up was undertaken to determine whether sampled patients and comparison subjects had
developed urological cancers in the subsequent 5 years.
Results: We found that urological cancers occurred among 0.54% of patients with ADs and 0.13% of comparison
subjects. After adjusting for sociodemographic characteristics, medical comorbidities, and alcohol and tobacco use
disorder, the stratified Cox proportional hazard regression suggested that patients with ADs were more likely to
develop urological cancers relative to comparison subjects (adjusted hazard ratio, 3.67; 95% confidence interval, 2.
85 ~ 4.72). The adjusted HR for males with ADs was 3.82 (95% CI: 2.79 ~ 5.23) in comparison to males without ADs.
In addition, the adjusted HR for females with ADs was 3.47 (95% CI: 2.26 ~ 5.31) than those females without ADs.
Conclusions: We concluded that during the 5-year follow-up period, there was a significantly increased risk of
urological cancers among patients with ADs.
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Background
Anxiety disorders (ADs), including panic disorder, gen-
eralized anxiety disorder, phobic disorder and so on,
are common mental disorders within a disease category
characterized by excessive worry which might affect
9.2% ~ 28.7% of the general population around the world
[1, 2]. The prevalence of ADs is not only high but also
strikingly increasing in Asian populations [3, 4].
ADs are shown to markedly compromise the quality of
life and psychosocial functioning in several domains [5].
ADs are highly comorbid with numerous chronic med-
ical illness including diabetes, coronary artery disease,
congestive heart failure, asthma, chronic obstructive pul-
monary disease, and arthritis [6, 7]. Thus, the research
focus has gradually turned to the relationship between
ADs and malignancies. Indeed, psychological distress
was proven to have an adverse effect on cancer survival
[8, 9].
Nevertheless, it is still controversial and unclear
whether the existence of ADs is associated with the
subsequent occurrence of cancer [8, 10–13]. Patients
with ADs were found to be at increased risks of devel-
oping specific cancer types including lung, brain, and
prostate cancers [11–13]. Although the underlying mech-
anism remains obscure, indirect relationships through a
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surveillance bias and unhealthy lifestyle behaviors were
proposed to interpret this association [12, 13]. It is debat-
able whether these factors could contribute to the overall
cancer risk instead of to certain cancer types such as
prostate and other urological cancers found in previous
studies.
It is possible that the weak, though significant, associ-
ation seen in previous studies lends support to a direct
relationship between ADs and urological cancers. Even
so, there is evidence that dysfunction of the serotonin
receptor pathway, crucial in anxiety disorders, might
also be involved in the proliferation of urological cancer
[14, 15]. This could pose a threat to both a patient's
mental and physical health. Considering the biological
plausibility, this study aimed to investigate the relationship
between ADs and the subsequent occurrence of urological
cancers using a longitudinal population-based database.
Methods
Database
The data for this retrospective cohort study were sourced
from the Taiwan Longitudinal Health Insurance Data-
base 2005 (LHID2005). The LHID2005, compiled by
the Taiwan National Health Research Institute, consists
of original medical claims data for 1,000,000 individuals
randomly sampled from all enrollees (n = 25.68 million)
in the Taiwan National Health Insurance (NHI) pro-
gram in 2005. Since around 96% of the Taiwanese
population enrolled in the NHI program, the LHID2005
provides an exclusive opportunity for researchers to
follow-up the use of all medical services for nationwide,
population-based sampled subjects. Hundreds of studies
utilizing this dataset have been published in internation-
ally peer-reviewed journals [16].
This study was exempt from full review by the Insti-
tutional Review Board of National Defense Medical Center
since the LHID2005 consists of de-identified secondary
data released to the public for research purposes.
Study sample
This study features a study cohort and a comparison
cohort. The study cohort included all patients who had
received one of the following ADs diagnoses between
January 1, 2001 and December 31, 2008: panic disorder
(ICD-9-CM: 300.01), generalized anxiety disorder (ICD-
9-CM: 300.02), phobic disorder (ICD-9-CM: 300.2,
300.20 ~ 300.29), obsessive-compulsive disorder (ICD-9-
CM: 300.3) and acute stress reaction & post-traumatic
stress disorder (ICD-9-CM: 308, 309.81 ~ 309.83) (n =
143,329). In order to increase the diagnosis validity, this
study only included patients with ADs who received at
least two anxiety disorder diagnoses with at least one
diagnosis having been made by a board-certified psych-
iatrist (n = 71,065). We assigned the date of the second
medical service utilization for ADs during the recruit-
ment period as the index date. We then excluded pa-
tients aged under 18 years (n = 1,961) in order to limit
the study to the adult population. Additionally, subjects
who had a history of major psychiatric disorders or a
substance-related disorder (ICD-9-CM codes 290 ~ 299
or 303 ~ 305) (n = 3,236) were excluded in order to
exclude possible confounding effects of other mental
illnesses on the association between ADs and urological
cancers. We further excluded those subjects who were
diagnosed with any type of cancer (ICD-9-CM codes
140 ~ 239) prior to the index date (n = 7,265). As a
result, 58,603 subjects with ADs were included in the
study cohort. The selection procedures were shown in
Fig. 1.
We likewise extracted the comparison cohort from the
LHID2005. We randomly selected one comparison sub-
ject for every study subject, matched by sex, age (18 ~
30, 30 ~ 39, 40 ~ 49, 50 ~ 59, 60 ~ 69, and >69 years),
and index year. While for the study cohort, the year of
the index date was the year in which the study subjects
received their first diagnosis of ADs, for the comparison
Fig. 1 Flow diagram for study cohort
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cohort, the year of the index date was simply a matched
year in which comparison subjects had a medical
utilization. We assigned the date of their first use of med-
ical services occurring during that matched year as the
index date for the comparison cohort. We ensured that no
selected comparison subjects had ever received a diagnosis
of ADs since initiation of the Taiwan NHI program in
1995. We also assured that no selected comparison sub-
jects had ever received a diagnosis of major psychiatric
disorders, substance-related disorder, or any type of can-
cer prior to the index date.
Thereafter, each patient in the study (n = 117,206) was
individually tracked for a 5-year period from their index
date to identify whether or not they had received a diag-
nosis of urological cancer (ICD-9-CM code185 ~ 189).
The diagnoses of urological cancers have been confirmed
by the registry of catastrophic illness. For the occurrence
of cancer to be reported in the registry, histological con-
firmation is required.
Statistical analysis
All statistical analyses were performed by the SAS statis-
tical package (SAS System for Windows, vers. 8.2, Cary,
NC, USA). We used the Kaplan-Meier method to estimate
the 5-year cancer-free survival rate and the log-rank test
to examine differences in the risks of urological cancer
xbetween these two cohorts. We used stratified Cox pro-
portional hazard regressions, stratified by sex, age group,
and index year to calculate the cancer hazard for the study
cohort relative to the comparison cohort. We adjusted for
demographic and socioeconomic characteristics, medical
comorbidities, and alcohol and tobacco use in the regres-
sion model. The variables of socioeconomic characteristics
included monthly income (New Taiwan (NT)$0 ~ 15,840,
NT$15,841 ~ 25,000, ≥NT$25,001; the average exchange
rate in 2011 was US$1 ≈NT$29), geographical location
(northern, central, eastern, and southern Taiwan), and
urbanization level of each subject’s residence (5 levels,
with 1 indicating the most urbanized and 5 the least ur-
banized). NT$15,840 was used as the first cut-off value
as it is the government-stipulated minimum wage for
full-time employees in Taiwan. Medical comorbidities
selected in this study were hypertension, diabetes, obes-
ity, alcohol abuse, and tobacco use disorder. All med-
ical comorbidities were defined by using ICD-9-CM
codes in LHID2005. In addition, we censored subjects
who died from non-cancer causes during the 5-year
follow-up period in the regression model. Of the sam-
pled subjects, 3749 died from non-cancer causes, in-
cluding 2051 from the study cohort (3.5% of study
cohort) and 1698 from the comparison cohort (2.9% of
the comparison cohort). The differences were consid-
ered significant with a two-sided p value of ≤0.05.
Results
Of the 117,206 study subjects, the mean age was 51.0 years
(standard deviation, 16.5 years), while they were 51.1 years
for the study cohort and 50.9 years for the comparison
cohort (p = 0.209). Table 1 shows the demographic and
socioeconomic characteristics of subjects with and with-
out ADs. The overwhelming majority (61.8%) of study
subjects were female, and over half were aged <50 years
(about 57%). There were significant differences between
the study and comparison cohorts in terms of monthly
Table 1 Subjects with anxiety disorder and a comparison group
in relation to sociodemographic characteristics and medical







No. Percent No. Percent
Sex 1.000
Male 22,394 38.2 22,394 38.2
Female 36,209 61.8 36,209 61.8
Age (years) 1.000
<40 19,722 33.8 19,722 33.8
40 ~ 49 13,269 22.7 13,269 22.7
50 ~ 59 10,654 18.2 10,654 18.2
60 ~ 69 7,405 12.7 7,405 12.7
>69 7,323 12.6 7,323 12.6
Monthly income <0.001
≤NT$15,840 24,159 41.2 23,299 39.8
NT$15,841 ~ 25,000 22,503 38.4 22,108 37.7
≥NT$25,001 11,941 20.4 13,196 22.5
Geographic region <0.001
Northern 25,542 43.6 27,622 47.1
Central 16,292 27.8 13,642 23.3
Southern 15,574 26.6 15,797 27.0
Eastern 1,195 2.0 1,542 2.6
Urbanization level <0.001
1 (most urbanized) 16,858 28.8 17,685 30.2
2 16,235 27.7 16,224 27.7
3 8,593 14.7 9,509 16.2
4 9,217 15.7 8,288 14.1
5 (least urbanized) 7,700 13.1 6,897 11.8




790 1.4 69 0.1 <0.001
Tobacco use disorder 1,497 2.6 355 0.6 <0.001
Diabetes 6,611 11.3 5,483 9.4 <0.001
Hypertension 18,871 32.2 12,041 20.6 <0.001
Note: In 2011, the average exchange rate was US$1 ≈New Taiwan (NT) $29
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income, geographical location, and urbanization level of
each subject’s residence. In addition, subjects with ADs
had a higher prevalence of medical comorbidities of
hypertension, diabetes, obesity, and alcohol and tobacco
use problems than subjects without ADs (all p < 0.001).
Table 2 presents the incidence rate for a new uro-
logical cancer diagnosis by cohort within the 5-year
follow-up period. Of the 117,206 subjects, 391 (0.33%)
received a diagnosis of urological cancer: 315 in the
study cohort (0.54% of the subjects with anxiety dis-
order) and 76 in the comparison cohort (0.13% of sub-
jects without anxiety disorder). The incidence rates of
urological cancers during the 5-year follow-up period
were 10.93 (9.76 ~ 12.21) per 10,000 person-years for
the study cohort and 2.62 (2.07 ~ 3.28) per 10,000
person-years for the comparison cohort. The log-rank
test revealed that subjects with ADs had a significantly
lower 5-year urological cancer-free survival rate than
comparison subjects (p = 0.005). Figure 2 presents re-
sults of the Kaplan-Meier survival analysis.
Results of the stratified Cox proportional regressions
(stratified on sex, age group, and index year) are also
presented in Table 2. The crude hazard ratio (HR) for
urological cancer during the 5-year follow-up period
for the study cohort was 4.16 (95% confidence interval
(CI): 3.23 ~ 5.34) with respect to the comparison cohort.
After adjusting for urbanization level, monthly income,
geographic region, hypertension, diabetes, obesity, and al-
cohol and tobacco use, and censoring cases that died from
non-cancer causes, the HR for urological cancer during
the 5-year follow-up period for study cohort was 3.67
(95% CI: 2.85 ~ 4.72) that of comparison patients.
Table 3 presents the proportional HRs of subgroups
classified by the type of urological cancers (kidney
cancer, bladder cancer, prostate cancer, and others).
The adjusted HRs for kidney cancer, bladder cancer,
prostate cancer, and others for subjects with ADs were
2.84 (95% CI: 1.73 ~ 4.66), 2.94 (95% CI: 1.89 ~ 4.58),
4.67 (95% CI: 3.06 ~ 7.12), and 6.75 (95% CI: 2.01 ~
22.69), respectively, relative to those without ADs.
The incidences of urological cancers within 5 years after
the index date between patients with ADs and those
without ADs stratified by sex are presented in Table 4.
The adjusted HR for males with ADs was 3.82 (95% CI:
2.79 ~ 5.23) in comparison to males without ADs. In
addition, the adjusted HR for females with ADs was 3.47
(95% CI: 2.26 ~ 5.31) than those females without ADs.
Discussion
A relationship exists between ADs and the subsequent
occurrence of urological cancers, as suggested by the
results herein. The findings of this study were consistent
with previous reports [12, 13]. Shen and colleagues
reported that male patients with generalized ADs had an
increased standardized incidence ratio (SIR) for prostate
cancer (2.17, 95% CI: 1.56 ~ 2.93) [13]. Since the preva-
lence of ADs in the general population is substantial, the
observed SIR may introduce bias and cause underesti-
mation of the true relative risk [17]. Another study by
Liang and colleagues only demonstrated an increased
risk of developing prostate cancer among patients with
ADs older than 65 years [12]. The failure to exclude co-
morbid psychiatric disorders made the study group more
heterogeneous which could have biased the results to-
ward zero.
Both studies argued that the higher risk of prostate
cancer could be partially explained by a surveillance
bias. Patients with ADs were likely to search for med-
ical help and thus might have received more imaging
and laboratory examinations [6, 7, 18]. If true, the over-
all risk of cancer should also increase among patients
with ADs, which was not supported by previous study
results. Patients with ADs have more urological com-
plaints [19, 20]. Liang and colleagues further validated
their assumption regarding a surveillance bias by show-
ing a higher prostate-specific antigen (PSA) screening
rate among patients with ADs [12]. However, the pro-
posed explanation is difficult to apply to the signifi-
cantly increased risks of urological cancers other than
prostate cancer among patients with ADs.
Another explanation stems from unhealthy lifestyles
and medication use among patients with ADs. Patients
with ADs tend to be overweight and physically inactive
and are more likely to use alcohol and tobacco [21, 22].
Table 2 Hazard ratios (HRs) and 95% confidence intervals (CIs) of urological cancer among sampled subjects during the 5-year
follow-up period from the index date
Presence of urological cancer Total sample n = 117,206 Patients with anxiety disorder n = 58,603 Comparison cohort n = 58,603
No. Percent No. Percent No. Percent
Yes 391 (0.33) 315 (0.54) 76 (0.13)
Incidence rate per 10,000 person-years (95% CI) 6.76 (6.11 ~ 7.47) 10.93 (9.76 ~ 12.21) 2.62 (2.07 ~ 3.28)
Crude HR a(95% CI) – 4.16*** (3.23 ~ 5.34) 1.00
Adjusted HRb (95% CI) – 3.67*** (2.85 ~ 4.72) 1.00
Notes: aStratified Cox proportional regression stratified on patients’ sex, age group, and index year. bAdjusted for patients’ monthly income, urbanization level,
geographic region, hypertension, diabetes, obesity, tobacco use disorder, and alcohol abuse/alcohol dependence syndrome
***p < 0.001
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In addition, a stress-prone personality and unfavorable
coping styles commonly seen among patients with ADs
might place them at a higher cancer risk [8]. Even so,
the overall cancer risks were not consistently high in
previous studies [11, 12].
In an earlier comprehensive review of the relationship
between lifestyle issues and urological cancers, only strong
connections of tobacco use with bladder and renal cancers
were repeatedly supported by the literature [23]. Other
lifestyle risk factors, if they existed, had only modest im-
pacts on the development of urological malignancies. Fur-
thermore, patients with ADs remained at a significantly
high risk of developing all kinds of urological cancers after
adjusting for tobacco use disorder in this study.
The long-term use of psychotropic medications, par-
ticularly benzodiazepine anxiolytics, is prevalent among
patients with ADs. However, study results of the car-
cinogenic potential of benzodiazepine anxiolytics remain
equivocal [24, 25]. Kao and colleagues reported that pa-
tients with a history of taking benzodiazepine were more
likely to develop prostate and bladder/kidney cancers
with respective HRs of 1.72 and 1.76 [24]. There is still
no specific mechanisms or explanations which account
for the observed increased risk, and their findings were
challenged for failing to control numerous confounding
factors [26].
The current study demonstrated that patients with ADs
were more likely to develop prostate cancer after adjusting
for available demographic, socioeconomic, and comorbid
medical and substance use variables. A direct mechanism
linking ADs itself to urological cancers should not be
neglected.
As stated before, stress-related psychosocial factors can
have adverse effects on cancer incidence and survival by
disturbing functions of the immune system, thus enhan-
cing the risk of carcinogenesis [27]. Lines of evidence
Fig. 2 Urological cancer-free survival rates for subjects with anxiety
disorder and comparison subjects
Table 3 Hazard ratios (HRs) and 95% confidence intervals (CIs) of urological cancer among sampled subjects during the 5-year
follow-up period from the index date according to the type of urological cancer
Presence of urological cancer Patients with anxiety disorder n = 58,603 Comparison cohort n = 58,603
No. Percent No. Percent
Kidney cancer
Yes 67 (0.11) 21 (0.04)
Incidence rate per 100,000 person-years (95% CI) 23.20 (17.98 ~ 29.47) 7.24 (4.48 ~ 11.07)
Adjusted HRa,b (95% CI) 2.84*** (1.73 ~ 4.66) 1.00
Bladder cancer
Yes 88 (0.15) 26 (0.04)
Incidence rate per 100,000 person-years (95% CI) 30.48 (24.45 ~ 37.55) 8.97 (5.86 ~ 13.14)
Adjusted HRa,b (95% CI) 2.94*** (1.89 ~ 4.58) 1.00
Prostate cancer (men only)
Yes 138 (0.62) 26 (0.12)
Incidence rate per 10,000 person-years (95% CI) 12.53 (10.53 ~ 14.81) 2.35 (1.53 ~ 3.44)
Adjusted HRa,b (95% CI) 4.67*** (3.06 ~ 7.12) 1.00
Others
Yes 22 (0.04) 3 (0.01)
Incidence rate per 100,000 person-years (95% CI) 7.62 (4.77 ~ 11.53) 1.04 (0.21 ~ 3.02)
Adjusted HRa,b (95% CI) 6.75** (2.01 ~ 22.69) 1.00
Notes: aStratified Cox proportional regression stratified on patients’ sex, age group, and index year. b Adjusted for patients’ monthly income, urbanization level,
geographic region, hypertension, diabetes, obesity, tobacco use disorder, and alcohol abuse/alcohol dependence syndrome
**p < 0.01, ***p < 0.001
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suggest that persistent activation of the hypothalamic-
pituitary-adrenal (HPA) axis can alter the function of
the neuroendocrine system, disrupt the circadian gluco-
corticoid rhythm, and thus promote tumor initiation and
progression [28–31]. More specifically, stress-related neu-
rotransmitters such as serotonin were proposed as being
correlated with the progression of urological cancers
[32, 33].
As an important monoamine neurotransmitter in the
brain, serotonin plays a crucial role in the neurobio-
logical processing of anxiety. Dysregulation of serotonin
is strongly associated with the development of ADs
[34]. Serotonin also serves as a messenger that controls
several processes of the body including carcinogenesis.
Siddiqui and colleague found that serotonin could in-
crease the proliferation of bladder cancer cells in vitro
in a dose-dependent manner and could modify the
growth inhibitory effect of doxazosin on prostate and
bladder cancer cells [15, 35]. Based on relevant find-
ings, serotonin was proposed to be a prognostic marker
for urological cancer [36]. Although the majority of
previous studies were conducted in vitro and clinical
applications remain controversial [37]. We argue that
dysregulation of the serotonin receptor pathway might
contribute to the relationship between ADs and uro-
logical cancers.
Lines of evidence support that traumatic experience
may alter core physiological systems and even cause
carcinogenesis through DNA breakage [38]. Traumatic
experience, even early childhood maltreatment, may in-
crease the risk of ADs [39]. On the other hand, effective
treatment such as psychotherapy could reverse DNA
damage [40]. There could be a remote and common cause
for both ADs and urological cancers. The strength of this
study comes from it utilizing a large, population-based
sample. Still, the results should be interpreted in light of
potential methodological limitations. First of all, the use of
non-standardized diagnoses made by different physicians
is an inherent problem with population-based studies. By
restricting our analyses to two visits with a diagnosis of
ADs with at least one having been made by a board-
certified psychiatrist, we enhanced the specificity of
the psychiatric diagnoses. Further, we chose a broad
approach to a diagnosis of ADs in order to reduce mis-
classification. Second, information about certain risk
factors for urological cancer including environmental
exposure, amount of tobacco and alcohol use, body
mass index and family cancer history is not available in
the database. Information on traumatic events and
critical life events is also unavailable. We adjusted for
the geographical location and urbanization level of
each subject’s residence in the study. The diagnoses of
tobacco and alcohol use disorders, which represent the
most severe form of tobacco and alcohol use, were also
considered in our analyses. In addition, the LHID2005
provides no information about serotonin levels or the
serotonin axis. Consequently, we could not demonstrate
the notion whether serotonin is important in patients with
ADs developing bladder cancer. Still, a potential bias
could exist. And last, a 5-year follow up period was chosen
to ensure an adequate time window for the development
of urological cancers among subjects at risk. Some sub-
jects might have had a more-insidious onset and could
not be identified within the 5-year follow-up period.
Conclusions
Despite these limitations, we found that during the 5-year
follow-up period, the risk of developing urological caner
was much higher among patients with ADs, compared to
their counterparts without ADs, and this association was
totally independent from comorbid hypertension, diabetes,
obesity, and registered alcohol and tobacco use disorders.
Clinicians should be aware of the increased risk of devel-
oping urological cancer among patients with ADs and are
encouraged not to neglect relevant urological complaints.
Abbreviations
ADs: Anxiety disorders; HR: hazard ratio; LHID2005: Longitudinal health
insurance database 2005; NHI: National health insurance; SIR: Standardized
incidence ratio.
Table 4 Hazard ratios (HRs) and 95% confidence intervals (CIs) of urological cancer among sampled subjects during the 5-year
follow-up period from the index date according to sex
Presence of urological cancer Males Females
Patients with anxiety




disorder (n = 36,209)
Comparison cohort
(n = 36,209)
No. Percent No. Percent No. Percent No. Percent
Yes 209 (0.93) 49 (0.22) 106 (0.29) 27 (0.07)
Incidence rate per 10,000 person-years (95% CI) 19.01 (16.52 ~ 21.77) 4.43 (3.27 ~ 5.85) 5.95 (4.87 ~ 7.19) 1.51 (0.99 ~ 2.19)
Crude HRa (95% CI) 4.28*** (3.14 ~ 5.85) 1.00 3.93*** (2.58 ~ 6.00) 1.00
Adjusted HRb (95% CI) 3.82*** (2.79 ~ 5.23) 1.00 3.47*** (2.26 ~ 5.31) 1.00
Notes: aStratified Cox proportional regression stratified on patients’ age group and index year
bAdjusted for patients’ monthly income, urbanization level, geographic region, hypertension, diabetes, obesity, tobacco use disorder, and alcohol abuse/alcohol
dependence syndrome. ***p < 0.001
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